A phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Japanese Subjects with Advanced Solid Tumors or Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs DS 3032b (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 13 Feb 2017 Planned End Date changed from 30 Sep 2016 to 31 Mar 2017.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 New trial record